Prestige traces its roots to 1996, when its predecessor began assembling consumer brands. Private equity firm GTCR acquired the business in 2004, and Prestige Brands Holdings went public on the NYSE in February 2005. The early portfolio mixed OTC medicines, personal care and household cleaners such as Comet and Spic and Span. Over the following decade the company bought larger OTC portfolios, sold the household cleaning business and in 2018 renamed itself Prestige Consumer Healthcare to reflect its pure OTC focus.
The Acquisition Model
Prestige buys established OTC brands that larger healthcare companies no longer prioritize, then supports them with focused marketing and retail execution. Major deals include 17 GSK brands for $660 million (2012), C.B. Fleet for $825 million (2017), Akorn's consumer health business for $230 million (2021), and Breathe Right and other brands for $1.045 billion (2026).
Asset-Light Supply Chain
Most products are made by contract manufacturers, which keeps capital spending low but exposes the company to supplier problems. Limited Clear Eyes supply was the main reason FY2026 revenue fell 4.3%, prompting the 2025 purchase of Clear Eyes maker Pillar5 Pharma.
